The company's claims for the invention titled oral compositions of Diacerein or salts thereof with reduced soft stool, include an oral pharmaceutical composition comprising 20-45 mg of rhein or diacerein, or salts, characterised in the composition showing at least 25 per cent reduction in soft stool effect as compared to a 50 mg diacerein formulation marketd under the trade name Art 50.
The First Examination Report, on the application, while examining the claims, raised objections that the first three claims do not meet the requirements of clarity and the application does not meet the criteria of inventive step.
The company filed a reply to the objections that the Patent raised.
The applicants have amended claims with addition of additional matter, which is beyond the scope of earlier claimed claims, such an amendments is out of scope of Section 59 read with section 57 of the Patent Act and therefore not allowable, stated the order.
"The pills are useful against osteoarthritis. The problem solved by the present invention may be regarded as the provision of an alternative galenical form providing increased bioavailability of the specified drugs. However, the company's claim on 25 per cent reduction in soft stool effect of the drug, is merely a statement of problem while it should set out how the desireable properties are obtained," the Patent Office noted.
While the Patent Office scheduled a hearing seeking further clarification on the reply to the FER objectioins, the company representatives did not attend the scheduled hearing, leaving the objections raised at various stages as outstanding.
"On consideration of all the documents available on record and in view of above outstanding objections raised /communicated at various stages during the prosecution of application are still remain outstanding as on the date , accordingly, I refuse to proceed further on this Patent Application," the order stated.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)